ArticleCancers2021

First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.

Chi-Leung Chiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.